Pictet Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pictet Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.46M	Sell	471,573 -268,937	-36%	-$2.09M	﹤0.01%	796
2025 Q4	$5.71M	Sell	740,510 -455,809	-38%	-$3.3M	0.01%	781
2025 Q3	$9.03M	Buy	1,196,319 +227,278	+23%	+$1.89M	0.01%	692
2025 Q2	$9.06M	Buy	969,041 +356,717	+58%	+$3.32M	0.01%	670
2025 Q1	$4.8M	Buy	612,324 +585,882	+2,216%	+$4.73M	0.01%	807
2024 Q4	$199K	Buy	26,442 +6,840	+35%	+$51.9K	﹤0.01%	1859
2024 Q3	$149K	Hold	19,602	–	–	﹤0.01%	1894
2024 Q2	$121K	Hold	19,602	–	–	﹤0.01%	1862
2024 Q1	$99.6K	Hold	19,602	–	–	﹤0.01%	1882
2023 Q4	$117K	Sell	19,602 -4,172,698	-100%	-$24.2M	﹤0.01%	1855
2023 Q3	$29.7M	Buy	+4,192,300	New	+$30.1M	0.04%	368

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Pictet Asset Management's BCRX Position: Q1 2026 in Review

Pictet Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 36% in Q1 2026, selling an estimated $2.09M and leaving 471,573 shares worth $4.46M. The position accounts for ﹤0.01% of the portfolio, ranked #796.

Pictet Asset Management first reported a position in BCRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $29.7M in Q3 2023. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Pictet Asset Management held 471,573 shares of BioCryst Pharmaceuticals worth $4.46M as of Q1 2026.
Pictet Asset Management sold 268,937 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $2.09M.
BioCryst Pharmaceuticals made up ﹤0.01% of Pictet Asset Management's portfolio in Q1 2026, its #796 holding.
Pictet Asset Management first reported a position in BioCryst Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Pictet Asset Management's BioCryst Pharmaceuticals position peaked at $29.7M in Q3 2023.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.